Mexico City, 14 Apr (EFE). Five Latin American countries are very advanced in implementing the personalized medical denomination that favors a more centralized environment and the patients that enforce it, according to The Economist Intelligence Unit.
It informs, “Personalized Medicine in Latin America: Universalizing the Promise of Innovation”, elaborated with the support of Latin American Roche, analyzes the new countries of the region and the classics at three levels according to their degree of advancement.
Destination Argentina, Brazil, Colombia, Costa Rica and Uruguay are subject to advancement conditions and the adoption of a personalized medical attention scale, although these nations have important vacancies in their evaluation.
Aleyda Tavira, Roche’s Personalized Medicine Leader, explains that while there are more advanced countries than others, the truck to implement this type of attention span is starting to forge.
Explain that personalized medicine is not focused on treating patients, both people and people, which promises to have a diagnostic “for which there is no delay, temperature and accuracy” and that there is a monitor and attention to distance, for which purpose the new technologies.
Details that this new approach can be used to improve the diagnosis and treatment of cancer, and that physicians can take therapeutic decisions precisely to achieve more reliable results.
In addition, it helps robust health systems, mediates the efficient use of resources, and imparts them with its sustainability to a large extent.
Medical advances, technology, genomics and the science of confusing data in this new medical field, in addition to the potential to improve patient outcomes, allow health care systems to take decisions based on data.
According to The Economist, in order to adopt the personalized medicine, the countries should meet with models of value-based attention, digitalisation of health (including electronic medical records), incorporation of real world evidence in normative processes and Evaluation.
For Tavira, one of the keys is the use of information to better understand the illnesses and personalization of the treatments, the ones that do not have to be alone with the pharmacological therapies we have with the owner and other factors.
“The objective is to consider relevant aspects that cover the patient to give the patient a greater attention”, indicated.
However, completing this type of metas is complicated and the majority of countries, especially Latin Americans, introduce important remarks to alcanzarlas.
Between these challenges, the report results in the failure of voluntary politics, the maintenance of a holistic vision, inefficient regulations and a vision that pervades health as a guest during an inversion.
Because of this, Latin American countries have already taken some initial steps on the road to personalized medicine, but there is much to be done to ensure that these innovations are available to the general public.
“Appears a sublime, but it is possible. Undoubtedly, there are more advanced countries than others, so it works to follow suit”, he points out.
(c) EFE Agency